News

April 2014 Incanthera is granted a patent in the United States, expanding protection for ICT01-2588

The Company’s most advanced programme, ICT01, focuses on the development of a new anticancer agent, which has been dubbed a ‘smart bomb’.  ICT01 releases a warhead when in contact with an enzyme specifically released by a cancer. Preclinical in vitro and in vivo data are very encouraging and company is preparing the programme for a Phase I clinical trial.

The Company owns patent families protecting ICT01 and a key patent has been granted in April 2014 in the United States.

Dr Simon Ward, CEO: “The grant of the US patent for our ICT01 programme is very important to the company and its commercial ambitions. Protection in the US offers exclusivity in this very important market. This in turn increases the commercial value of the asset. We believe our continuous effort to bring novel anticancer agents to the clinic will offer improved treatment to patients.”